Antibody avidity

Avidity in antibody effector functions and biotherapeutic drug design

Read about the role of avidity in antibody functional responses and strategies to manipulate avidity in the design of antibody-based therapies in this Review in the October issue         

  • Simone C. Oostindie
  • Greg A. Lazar
  • Paul W. H. I. Parren
Review Article

Announcements

  • Image of RNA

    As RNA medicines continue to change the face of clinical practice, this conference explores progress in our understanding of the roles of RNAs in immune signaling, chronic disease associated with dysregulated inflammation and efforts to translate basic knowledge into mRNA vaccines and oligonucleotide treatment

  • Picture of poster

    Following the landmark approval of imatinib two decades ago, over 70 kinase inhibitors are transforming the treatment of cancer and other disorders. This poster highlights key advances in this period, including the increased molecular and structural understanding of kinases and strategies to combat resistance to kinase inhibitors in cancer therapy.

Advertisement

    • The ‘predictive validity’ of decision tools such as disease models that are used in drug research and development (R&D) — the degree to which the output from a tool correlates with clinical utility in people — has a major influence on R&D productivity. This article explains this influence and discusses methods to evaluate and improve the predictive validity of decision tools, with the aim of supporting the application of more effective tools and catalysing investment in their creation.

      • Jack W. Scannell
      • James Bosley
      • J. Mark Treherne
      Perspective
    • The exploitation of cytokines for therapeutic use has been limited by their pleiotropic activity, which has contributed to dose-limiting toxicity and lack of efficacy. Here, Garcia and colleagues discuss how recent insights from structural biology, protein engineering and receptor pharmacology have unveiled strategies to overcome cytokine pleiotropy and enable the design of new and improved cytokine-based therapeutics.

      • Robert A. Saxton
      • Caleb R. Glassman
      • K. Christopher Garcia
      Review Article
    • The rational discovery of covalent drugs depends on an expanding toolset of techniques. Here, Daniel Nomura and colleagues highlight covalent drugs that have achieved success over the past decade and discuss the tools and strategies that facilitate their discovery, describing two complementary approaches, namely, ligand-first and electrophile-first strategies.

      • Lydia Boike
      • Nathaniel J. Henning
      • Daniel K. Nomura
      Review Article
    • Peptide and protein drugs have proven successful in the treatment of a wide range of diseases, but their use can be limited by their inherent short-life and need for parenteral administration. Here, Kurtzhals et al. discuss how fatty acid derivatization can be applied to address these issues and optimize the pharmacological properties of peptide and protein drugs, highlighting associated considerations and future directions.

      • Peter Kurtzhals
      • Søren Østergaard
      • Thomas Kjeldsen
      Review Article
    • This Review provides an update on the application of small-molecule drugs in immuno-oncology, discussing current development of small molecules designed to stimulate the antitumour immune response directly and indirectly, and the rapidly increasing efforts towards the discovery of small molecules that target T cell checkpoints.

      • Rienk Offringa
      • Lisa Kötzner
      • Klaus Urbahns
      Review Article

Nature Careers

Events

Advertisement